Efficacy of the Aspen Spinous Process System in Anterior Lumbar Interbody Fusion (ALIF)

NCT ID: NCT01016314

Last Updated: 2019-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, prospective randomized clinical study to evaluate the clinical outcome of subjects with degenerative disc disease (DDD) treated with ALIF and supplemental posterior fixation using ASPEN Spinous Process System compared to pedicle screw instrumentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, prospective randomized clinical study to evaluate the clinical outcome of subjects with DDD who are treated with ALIF and supplemental posterior fixation using Aspen compared to pedicle screw instrumentation. The study will involve up to approximately 25 investigational sites and enroll up to 156 67 subjects. The randomization ratio of two Aspen subjects to one pedicle screw subject (2:1) will be utilized.

Subjects with lumbar DDD who are candidates for ALIF at a single level will be screened for inclusion in the study. If the subject meets all of the eligibility criteria, they will be enrolled and randomized to either the Aspen or pedicle screw group. Subjects will continue to be followed by the guidelines set forth in this clinical protocol, which include: a postoperative discharge exam; six week, three month, six month, and one year post-op visits; and, concludes with a two year post-op visit. The follow-up is counted from the day of surgery. The enrollment period is expected to be approximately 12 months and subjects will be followed for 2 years post-op for the duration of the clinical investigation. The anticipated duration of the study is approximated to be 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspen Spinous Process System

Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.

Group Type EXPERIMENTAL

Aspen Spinous Process System

Intervention Type DEVICE

Aspen Spinous Process System is an interspinous process fixation device

Pedicle Screw Fixation

Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.

Group Type ACTIVE_COMPARATOR

Pedicle Screw Fixation

Intervention Type DEVICE

Pedicle Screws are used for the fixation of the spine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aspen Spinous Process System

Aspen Spinous Process System is an interspinous process fixation device

Intervention Type DEVICE

Pedicle Screw Fixation

Pedicle Screws are used for the fixation of the spine

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 75 years
* Scheduled for an elective single level ALIF with posterior fixation
* Diagnosis of primary symptomatic DDD confirmed with appropriate imaging studies and/or positive lumbar discography
* Oswestry Disability Index (ODI) v 2.1 score \>30%
* Failed at least 6 weeks of conservative care (non-surgical)/clinical signs of neurological deterioration
* No contraindications for ASPEN spinous process system (at the discretion of the investigator)

Exclusion Criteria

* Prior lumbar fusion surgery at any level (prior discectomy and/or laminectomy allowed)
* Spondylolisthesis grade 3 or more
* Lytic spondylolisthesis
* Incompetent or missing posterior arch at the affected level (e.g. laminectomy, pars defect)
* Currently requires laminectomy at level of surgery
* Facet joints at implant level are absent or fractured
* Post-traumatic vertebral body compromise or acute fracture at implant level
* Body mass Index (BMI) \> 40
* Known allergy to titanium
* Osteoporosis: SCORE (Simple Calculated Osteoporosis Risk Estimation) will be used to screen subjects who require DEXA. Subjects with T-score \< -2.5 will be excluded
* Paget's disease, osteomalacia, or any other metabolic bone disease
* Use of medications or any drug known to potentially interfere with bone/soft tissue healing (e.g. chronic systemic steroids)
* Planned use of Bone Morphogenetic Protein (BMP)
* Unlikely to comply with the follow-up evaluation schedule
* Subject has recent history (less than 3 years) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation
* Participation in a clinical trial of another investigational drug or device within the past 30 days
* Systemic infection such as AIDS, HIV, and active hepatitis
* Active malignancy defined as history of invasive malignancy, except if the subject has received treatment and displayed no clinical signs and symptoms for at least five years
* Pregnant or planning to become pregnant during the length of study participation
* Involvement in active litigation related to back problems at the time of screening
* Direct involvement in the execution of this protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zimmer Biomet

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kee Kim, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pomona Valley Hospital Medical Center

Pomona, California, United States

Site Status

University of California, Davis

Sacramento, California, United States

Site Status

Kansas University Medical Center

Kansas City, Kansas, United States

Site Status

New York University School of Medicine

New York, New York, United States

Site Status

South Texas Spine

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASP-09-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

OLIF25™ /OLIF51™ Study
NCT02657421 TERMINATED
Titanium vs. PEEK Fusion Devices in 1 Level TLIF
NCT05691062 ENROLLING_BY_INVITATION PHASE4